- Home
- AGAE vs CLSD Comparison
AGAE vs CLSD Comparison
Compare AGAE & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGAE
- CLSD
- Stock Information
- Founded
- AGAE 2017
- CLSD 2011
- Country
- AGAE United States
- CLSD United States
- Employees
- AGAE N/A
- CLSD N/A
- Industry
- AGAE Cable & Other Pay Television Services
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- AGAE Telecommunications
- CLSD Health Care
- Exchange
- AGAE Nasdaq
- CLSD Nasdaq
- Market Cap
- AGAE 73.8M
- CLSD 68.4M
- IPO Year
- AGAE N/A
- CLSD 2016
- Fundamental
- Price
- AGAE $1.11
- CLSD $3.59
- Analyst Decision
- AGAE
- CLSD Hold
- Analyst Count
- AGAE 0
- CLSD 4
- Target Price
- AGAE N/A
- CLSD $65.00
- AVG Volume (30 Days)
- AGAE 5.9M
- CLSD 57.9K
- Earning Date
- AGAE 11-13-2025
- CLSD 11-11-2025
- Dividend Yield
- AGAE N/A
- CLSD N/A
- EPS Growth
- AGAE N/A
- CLSD N/A
- EPS
- AGAE N/A
- CLSD N/A
- Revenue
- AGAE $8,254,861.00
- CLSD $4,166,000.00
- Revenue This Year
- AGAE N/A
- CLSD $98.20
- Revenue Next Year
- AGAE N/A
- CLSD $213.77
- P/E Ratio
- AGAE N/A
- CLSD N/A
- Revenue Growth
- AGAE 0.52
- CLSD N/A
- 52 Week Low
- AGAE $0.70
- CLSD $3.52
- 52 Week High
- AGAE $3.79
- CLSD $24.75
- Technical
- Relative Strength Index (RSI)
- AGAE 44.84
- CLSD 51.81
- Support Level
- AGAE $0.86
- CLSD N/A
- Resistance Level
- AGAE $2.28
- CLSD $5.33
- Average True Range (ATR)
- AGAE 0.20
- CLSD 0.18
- MACD
- AGAE 0.04
- CLSD 0.14
- Stochastic Oscillator
- AGAE 17.84
- CLSD 67.13
About AGAE Allied Gaming & Entertainment Inc.
Allied Gaming & Entertainment Inc is an experiential entertainment company focused on providing a growing world of gamers with various experiences through renowned assets, products, and services.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.